Purpose: Drug resistance has become a major problem in the treatment of tuberculosis, and pulmonary resection in combination with chemotherapy appears to be an effective measure for the treatment. The purpose of this study was to investigate the results of resection for multidrug-resistant pulmonary tuberculosis (MDR-TB). Patients and Methods: We retrospectively reviewed case files from January 2003 to December 2006 of 13 patients with MDR-TB underwent pulmonary resection. Results: Of 13 patients, 7 (53.9%) were sputum positive for mycobacterium tuberculosis preoperatively, though after surgery, they were sputum negative. Lobectomy was performed in 8 (61.5%) and pneumonectomy, in 5 (38.5%). In the lobectomy group, 2 patients had an additional superior segmentectomy and 1 had a middle lobectomy for other segmental or lobar lesions. Operative mortality was 7.6% (1/13). There were no late surgical deaths. In the early postoperative period, 3 patients had serious complications (postoperative bleeding, prolonged air leak, expansion deficit, bronchopleural fistula and empyema) that were resolved with surgery (morbidity 23.0%). The 12 patients who survived the operation received appropriate chemotherapy and were followed up for 24-37 months. None of the patients relapsed, and the overall cure rate was 92.3% (12/13). Conclusion: Even with high morbidity in the early post-operative period, surgery, in addition to medical therapy, offers higher cure rates than only medical therapy; however, meticulous preoperative evaluation of patients is needed.
cal treatment.
1) The World Health Organization (WHO) estimates that there are nearly half a million new cases of multidrug-resistant pulmonary tuberculosis (MDR-TB) (about 5% of the total nine million new TB cases) worldwide each year.
2) The Turkish Ministry of Health reported 240 new MDR-TB cases (4.9%) in 2007. In these cases, resection of cavitary lesions, or destructive of a lobe or lung, would lower the bacilli count and possibly improve the efficiency of medical treatment. 3, 4) Even though the fluoroquinolone group of antibiotics may be effective in the treatment, the disease cannot be eliminated entirely.
5)

Introduction
Lung tuberculosis resistant to both isoniazid (INH) and rifampin (RMP) creates a serious health problem and the relapse can rise to a rate of up to 50% following medi-
Materials and Methods
Resistance to at least INH and RMP was regarded as multi-drug resistance. We retrospectively reviewed the records of 13 consecutive patients undergoing pulmonary resection for the treatment of MDR-TB in the Departments of Thoracic Surgery, Celal Bayar University, Faculty of Medicine, Manisa, Turkey and Dr. Suat Seren Chest Diseases and Thoracic Surgery Training Hospital, Izmir/TURKEY, from January 2003 to December 2006.
All of the 13 patients were resistant to at least both INH and RMP. Exclusions to the study were patients who had a positive drug susceptibility test and who were not cured during treatment with anti-TB drugs. Of 7 patients who were sensitive to the drugs, 3 underwent pulmonary resection for a destroyed lung, 2 had bronchiectasis, and 2, resection of a cavitary lesion. Preoperative examinations consisted of chest roentgenogram, computed tomography (CT), full blood analysis, biochemistry, arterial blood gas analysis, electrocardiogram, spirometry, acid-fast sputum smear, culture and drug susceptibility testing, if necessary, a quantitative perfusion scan, and fiber optic bronchoscopy. All patients were tested for drug susceptibility; however, because of technical limitations, we could only test susceptibility to INH, RMP, streptomycin (SM), and ethambutol (EMB). All patients were resistance to INH or RMP, 53.8% to EMB, and 30.7% to SM. The protocol for preoperative re treatment was designed to use at least four active drugs (range, 4-7; average, 5). The mean duration of anti-TB chemotherapy was 18 months (range, 6-36 months).
Indications for surgery were as follows: patients who were sputum-positive for mycobacterium tuberculosis after 4 to 6 months of appropriate second-line medical treatment (n = 7, 53.9%), patients who were sputum-negative and had significant pulmonary parenchymal lesions (n = 6, 46.1%); such as totally destroyed lung and/or large cavities, which would have a high probability of recurrence. Overall preoperative diagnoses included cavitations in 10 patients, and lung destruction in 3. In all 13 patients, the disease was localized in one lung as viewed in the radiographic film. Sequela of pulmonary nodular lesions in the other lung did not exclude the patients from the operation. With bilaterally cavitary lesions, resection could be done in separate sessions; however, none of the patients match these criteria. Surgery is planned for patients having adequate respiratory reserve and the localized disease. Standard pulmonary resection was performed through posterolateral thoracotomy incisions.
Bronchial isolation was achieved with double-lumen endotracheal tubes in all patients. During the surgery, especially in regions with dense fibrous cohesiveness, extrapleural dissection was made to remain the cavitary lesion intact. We used electrocautery to reduce the amount of bleeding during the extrapleural dissection. Lobectomy was performed in 8 patients (61.5%), and pneumonectomy was performed in 5 (38.5%). Of 3 patients in the lobectomy group, 2 had an additional superior segmentectomy and 1, a middle lobectomy, for other segmental or lobar lesions. The bronchial stump was closed with interrupted absorbable Vicryl suture (Ethicon, Somerville, NJ) in all patients. Intercostal muscle flap reinforcement of the bronchial stump was used in the 7 patients who were sputum positive. A sample of resected lung tissue was cultured to test for tuberculosis infection, and was subjected to routine histopathology including Ziehl-Nielsen staining. There were no cases of bilateral resection. After resection, the pleural space was irrigated with iodine and saline solution routinely. In the immediate postoperative period, anti-TB chemotherapy was started again. Duration of postoperative chemotherapy ranged between 18-24 months. "Operative mortality" was defined as a fatal outcome from a complication of lung resection within 30 days of the resection. "Late surgical death" was defined as demise, directly or indirectly related to surgery, occurring more than 30 days postoperatively.
Results
Of 13 patients, 9 men (69%) and 4 women (31%) with MDR-TB underwent a lung resection. The mean age was 44 years (range, 33-61 years). Of 13 patients, 4 were resistant to INH and RMP; 2, to INH, RMP and SM; 5, to INH, RMP, and EMB; and 2, to INH, RMP, SM, and EMB. The results of drug susceptibility testing are shown in Table 1 . Two patients were diabetic, and no patients tested positive for human immunodeficiency virus at the time of surgery. During surgery, no cavitary lesions were opened to the pleural space. The clinical profiles of 13 patients are displayed in Table 2 . Of 13 patients, 6 (46.1%) were sputum negative for mycobacterium tuberculosis preoperatively, and 7 patients (53.9%) showed persistent positive smear and culture tests. Sputum conversion was achieved in all of the sputum-positive patients (n = 7), giving a conversion rate of 100% postoperatively. Types of surgery and postoperative outcomes of 13 patients are displayed on Table 3 . One sputum-negative patient with limited respiratory function, required a right pneumonectomy, and he died on postoperative day 8 (operative mortality 7.6%). The overall, major morbidity rate was 23% (n = 3). Of 13 patients, 3 (23%) had postoperative complications including 1 (7.6%) with hemorrhage, 1 (7.6%)with prolonged air leak and space problem, and 1 (7.6%) with a bronchopleural fistula (BPF) and empyema. The patient with postoperative hemorrhage required a re exploration; the patients with a prolonged air leak and space problem responded to prolonged intercostal tube drainage, and the patient with postpneumonectomy bronchopleural fistulas with empyema (sputum positive preoperatively) was treated by open drainage (pleurocutaneous flap). None of the patients required multiple resections in separate sessions, completion pneumonectomy, or thoracoplasty. In the long-term follow up (24-37 months) the sputum test was negative and none of the patients relapsed either radiologically or bacteriologically.
Discussion
Medical treatment of MDR tuberculosis has a treatment failure rate of 40%-70% and is the leading cause of mortality for pulmonary tuberculosis. 1, 8) Surgery plays a decisive role in the overall management of MDR-TB and provides a somewhat better mortality and morbidity.
3-7)
Surgical resection is done because of the bacterial count within the cavity is high and antibiotic treatment fails to reach the site of infection. Thus, to cure the disease completely, it is imperative to resect the cavitary lesion and damaged lung tissue, leaving no grossly diseased lung behind. 3) In other retrospective studies, 3, 9) early mortality is reported to be under 3%; though, in this study, it was 7.6% because of the death of one patient (on postoperative day 8) who had a vital capacity of less than 50% and a low FEV ı , which necessitated a pneumonectomy, resulting from laceration of the main pulmonary artery during the hilar dissection. Significant morbidity of the surgical treatment is reported to be about 20%-25%. 4, 10, 11) Here, we report a 23% morbidity and 92.3% cure rate, which are comparable to other studies, bearing out the efficacy of surgery in the management of MDR-TB. In this study, 1 patient with dense adhesions in the chest wall and hilus underwent re thoracotomy for the bleeding. It is reported 12) that re thoracotomy for the bleeding is done because of the vascular nature of the adhesions. Takeda noted that blood loss for tuberculosis surgery is threefold larger than that during lung cancer surgery. 9) Prolonged air leak and space problems developed in 1 patient during the post operative period. The air leak responded to tube drainage, and the space that had filled with serous fluid did not become infected. The follow-up period was without incident. Pre operative sputum positivity, a recognized risk factor for bronchopleural fistula and post-pneumonectomy empyema, developed in 1 (7.6%) patient, even though we had used an intercostal muscle flap. This patient was treated by open drainage (pleurocutaneous flap). Although Pomerantz and Shiraishi advocate the routine use of muscle flap reinforcement of the bronchial stump, 3, 4) its use in patients with MDR-TB is debatable, because surgery without it had demonstrated adequate results. 6, 11, 13) On the other hand, many believe that maintenance of the peribronchial blood supply is critical. Minimal dissection and avoidance of electrical diathermy could prevent bronchopleural fistula. 11) Given that poor nutritional status, diabetes mellitus and sputum positivity at the time of surgery in patients are know to have higher rates of complications, we believe the morbidity in the present study is self-explanatory.
Most surgeons perform the surgery between 3 and 6 months after medical treatment, 13) because, according to Goble, 1) negative conversion could be achieved between 1 and 8 months, with a median of 2 months. We, however, were reluctant to recommend surgery for MDR tuberculosis so the patients in this study were treated with drugs over 18 months (range, 6 to 36) before surgery was attempted. We were cautious because a lobectomy or pneumonectomy for tuberculosis is considered to be a high-risk procedure and technically hazardous: the thorax fills with adhesions, scarring, and creates an area of chronic sepsis. 14) Even for experienced surgeons, hilar dissection may pose significant problems. 9) Postoperative antibiotic therapy is recommended for approximately 2 years after achieving a sterile sputum smear and culture. 15) All patients continued to take the medication 18-24 months postoperatively.
As a result, sputum conversion was achieved in all 7 patients, whose sputum originally tested positive for mycobacterium tuberculosis, giving a conversion rate of 100% postoperatively. Sputum smears and cultures continued to be negative to date. No patient died of recurrent MDR-TB. Late surgical death was nil, and the cure rate was 92.3%.
Though our experience is limited, we suggest that pulmonary resection is curative; however, ways must be found to reduce the morbidity. 
